Instil Bio Posts Wider Loss in Q2

Instil Bio (NASDAQ:TIL), a clinical-stage biotechnology company focused on developing immunotherapies for cancer, released its second quarter 2025 earnings on August 13, 2025. The report highlighted ongoing pipeline investment but underscored a widening loss and higher research costs. Non-GAAP EPS was $(2.88), missing analysts’ average estimate of $(2.50) by $0.38. The firm did not report any revenue, consistent with its pre-commercial status. Overall, the quarter showed measured clinical progress, but the absence of new efficacy data and escalating costs signal a continued uphill climb for the company. Source: Analyst estimates for the quarter provided by FactSet. Instil Bio develops antibody-based therapies for cancer. Its key product candidate is AXN-2510/IMM2510, a "bispecific antibody" that targets solid tumor cancers by aiming at two proteins involved in immune evasion and tumor blood supply. The company’s goal is to advance this candidate and other in-licensed therapies toward clinical proof-of-concept and eventual regulatory approval.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool